Christian Zurth
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial.
Journal: Targeted oncology
Published: March 17, 2023
Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment.
Journal: Clinical pharmacokinetics
Published: September 27, 2021
Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: November 10, 2020
Pharmacokinetics of Darolutamide, its Diastereomers and Active Metabolite in the Mouse: Response to Saini NK et al. (2020).
Journal: Drug metabolism letters
Published: August 28, 2020
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Journal: Targeted oncology
Published: October 02, 2019
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Journal: European journal of drug metabolism and pharmacokinetics
Published: October 02, 2019
Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
Journal: Cancer chemotherapy and pharmacology
Published: October 25, 2017
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
Journal: Cancer chemotherapy and pharmacology
Published: July 31, 2017
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.
Journal: Annals of nuclear medicine
Published: February 15, 2016
A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women.
Journal: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
Published: October 01, 2015
Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.
Journal: International journal of clinical pharmacology and therapeutics
Published: October 09, 2014
Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study.
Journal: International journal of clinical pharmacology and therapeutics
Published: August 21, 2014
Last Updated: 09/26/2026